To the Editor: A 19-year-old Chinese man, who received haploidentical allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute T-lymphoblastic leukemia 6 months ago, was evaluated for dysarthria, vomiting, high fever, and headache. Efforts to identify infectious pathogens all yielded negative results like cerebrospinal fluid (CSF) culture, serum toxoplasma antibody, serum galactomannan antigen assay, (1,3)-b-D-glucan antigen assay and tuberculosis (TB) interferon gamma release assay. His cerebral magnetic resonance imaging (MRI) showed multifocal mass and nodular mixed-density lesions with obvious peripheral edema in T2 sequence. An obvious eccentric target sign was observed in enhanced T1 sequence [ Figure 1 ]. Flow cytometry of his CSF revealed increased monocytes but no evidence of leukemic blasts. Although empirical antibiotics including imipenem and antifugal agents like caspofungin had been administered, he developed generalized epilepsy and coma in 2 weeks after admission. Thereafter emergent decompressive craniectomy and cerebral biopsy were conducted. Postsurgery pathology study found no signs of tumor but only a marked number of foamy macrophages in brain tissue. Hexamine silver staining and anti-fast staining failed to spot any germs. Finally, high-throughput pathogenic megagenomic sequencing of the biopsied tissue revealed abundance of Toxoplama gondii (T. gondii) genomes (7046 reads), which specifically led to the diagnosis of cerebral toxoplasmosis. Unfortunately, he failed pyrimethamine plus sulfadiazine therapy and died of uncontrolled disease.
Toxoplasmosis is an uncommon but potentially fatal opportunistic parasitic infection following allo-HSCT. Post-transplant toxoplasmosis is often a reactivation of prior latent infection and 90% of toxoplasmosis occur within the first 6 months after transplant.
[1] Serological testing of donor and recipient of allo-HSCT for T. gondii IgG is recommended and it is of critical importance for patients from endemic areas. [2] Delayed immune reconstitution like haploidentical allo-HSCT and continued immunosuppression for graft-versus-host disease are risk factors for T. gondii reactivation. [3] Typically, cerebral toxoplasmosis appears in MRI images as multiple lesions that are hypointense on T1-weighted pre-contrast MRI. On T2-weighted and fluid attenuated inversion recovery (FLAIR) MRI, the lesions are usually hyperintense with focal nodular or ring enhancement after administration of gadolinium contrast. [1] However, besides parasite, targeted signs on MRI image often suggest tumor growth, invasive fungal infection, and also TB. It is noteworthy that T. gondii antibodies may not be detected by ordinary serological assay in immunocompromised patients. Thus, the negative T. gondii IgG antibody test result in our patient was misleading. Brain tissue biopsy may be helpful in certain settings but sampling bias may also lead to false negativity.
Diagnostic metagenomics once working in research now has a role to play in identifying the pathogenic causes in clinical setting. [4] As in this case, the multiple intracranial lesions with a typical target sign on MRI was finally proven to be toxoplasmosis by megagenomic analysis after conventional methods failed to identify the responsible pathogen. This case has highlighted the potential of using high-throughout metagenomic analysis to identify unknown pathogens in difficult clinical settings.t
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